Innovative Bispecific Nanobody Targeting CD274 and TIGIT for Advanced Colon Cancer Immunotherapy

VHH-P364 is a humanized bispecific nanobody currently in the Biological Testing stage, designed to target both CD274 molecule (CD274) and T cell immunoreceptor with Ig and ITIM domains (TIGIT). This next-generation immunotherapeutic molecule aims to address significant unmet clinical needs in colon cancer by simultaneously modulating two critical immune checkpoint pathways. By integrating the specificity of monoclonal antibody engineering with the unique properties of nanobodies, VHH-P364 exemplifies the latest advancements in cancer immunotherapy, offering great potential for future colon cancer treatment strategies.

Licensing Opportunity

VHH-P364 is open for out-licensing and strategic collaborations. Partners interested in advancing cutting-edge immunotherapeutic solutions for colon cancer are encouraged to contact us for more information and partnership opportunities.

Development Phase

Modality

VHH-P364 is engineered as a bispecific fusion protein, consisting of an anti-human TIGIT humanized monoclonal IgG1 kappa antibody fused via a flexible linker to an anti-human CD274 nanobody. Expressed in HEK-293 cells, this nanobody-based format benefits from the single-domain structure, enabling smaller molecular size, superior tissue penetration, and increased binding versatility compared to traditional antibodies. The unique structural advantages of nanobodies, such as high stability and solubility, facilitate effective infiltration of dense tumor microenvironments like those found in colon cancer. This enhanced accessibility is critical for optimizing therapeutic efficacy in solid tumors.

Target

CD274 and TIGIT are essential immune checkpoint molecules involved in tumor immune evasion. CD274 is a membrane-bound ligand that acts to suppress anti-tumor T cell responses. TIGIT is an inhibitory receptor expressed on T cells and NK cells, regulating immune activation and tolerance. Both CD274 and TIGIT are often upregulated in colon cancer tissues and contribute to immune escape mechanisms, making them attractive therapeutic targets. Targeting CD274 and TIGIT in tandem with VHH-P364 can enhance anti-tumor immunity, overcoming resistance seen with monotherapy approaches. The simultaneous blockade of CD274 and TIGIT represents a strategic advancement for immunotherapy in oncology, reinforcing the asset value of VHH-P364.

Mechanism of Action

VHH-P364 acts as an immune checkpoint inhibitor by simultaneously binding to CD274 and TIGIT. Through dual engagement, the fusion protein effectively disrupts the inhibitory signaling pathways mediated by these checkpoints, leading to restoration and enhancement of anti-tumor immune responses. By blocking CD274, the molecule inhibits tumor-induced T cell suppression, while TIGIT antagonism releases additional brakes on cytotoxic lymphocytes. This dual mechanism offers synergy for tumor microenvironment modulation. Furthermore, the modularity of the nanobody platform supports potential derivation into additional therapeutic formats, including bispecifics and conjugates, amplifying the clinical and commercial versatility of VHH-P364.

Colon Cancer

Colon cancer is among the most commonly diagnosed malignancies worldwide and represents a significant cause of cancer-related morbidity and mortality. Current standard treatments include surgical resection, chemotherapy, radiation, and biological agents targeting key oncogenic pathways or immune checkpoints. While advances in targeted and immune-based therapies have improved patient outcomes, considerable limitations remain. Many patients either do not respond or eventually develop resistance to available agents, highlighting the critical need for novel therapeutic strategies. Immunosuppressive mechanisms within the tumor microenvironment, such as upregulation of CD274 and TIGIT, play a pivotal role in disease progression and therapeutic resistance. VHH-P364, by targeting both these checkpoints, holds promise for overcoming immune evasion in colon cancer and could address the pressing unmet need for durable, effective treatment options in both refractory and newly diagnosed cases.